Skip to main content
. 2016 Nov 21;35(3):352–360. doi: 10.1200/JCO.2016.67.5264

Fig 3.

Fig 3.

The Notch1 inhibitor brontictuzumab led to significant tumor growth inhibition exclusively in the ACCX9 patient-derived xenograft model harboring a NOTCH1 activating mutation (I1680N). Mice were treated with brontictuzumab by intraperitoneal injection at 10 mg/kg once every 2 weeks for two total doses, and mean tumor volume was assessed. Error bars indicate SEM. mut, mutated; WT, wild-type. (*) P < .05.